Can you provide a flow chart and algorithm for selecting and managing long‑acting injectable antipsychotic therapy, including loading doses, oral bridge requirements, injection intervals, and missed‑dose procedures?

Long-Acting Injectable Antipsychotic Algorithm and Flow Chart

Long-acting injectable antipsychotics should be offered to patients with schizophrenia who prefer this route or have poor/uncertain adherence, with selection based primarily on side-effect profiles and product attributes rather than molecule preference. 1

Patient Selection for LAI Therapy

Indications for LAI Consideration:

• History of poor or uncertain adherence (primary indication) 1
• Patient preference for LAI formulation 1
• Early phase schizophrenia to prevent irreversible relapse consequences 2
• Frequent relapses despite oral therapy
• Desire for consistent medication delivery without daily dosing

Contraindications/Cautions:

• Active substance use requiring stabilization first 3
• Medical conditions causing psychotic symptoms (delay until resolved) 3
• Pregnancy concerns (some agents like cariprazine require effective contraception) 3

---

LAI Selection Algorithm

Step 1: Prioritize Side-Effect Profile

Side effects are the most important consideration (ranked first by 33% of clinicians) 4

Decision Points:

• Metabolic concerns (weight gain, diabetes risk): Avoid olanzapine; consider aripiprazole formulations
• Extrapyramidal symptoms (EPS/akathisia risk): Prefer aripiprazole-based products over risperidone/paliperidone 5
• Sedation concerns: Avoid olanzapine
• Prolactin elevation: Avoid risperidone/paliperidone

Step 2: Consider Product Attributes

Product characteristics ranked second in importance (26% of high LAI users) 4

Key Attributes:

• Dosing interval: 63-82% of clinicians prefer monthly or longer vs. every 2 weeks 4
• Administration route: Subcutaneous (risperidone in situ, aripiprazole monohydrate SC) vs. intramuscular
• Injection site flexibility: Multiple site options increase likelihood of use 4
• Needle gauge/length: Smaller needles preferred 4
• Reconstitution requirements: Pre-filled syringes preferred over mixing required
• Refrigeration needs: Room temperature storage preferred
• Cost/insurance coverage: Must be addressed upfront 4

Step 3: Molecule Selection (Least Important)

Clinician preference for specific molecule ranked least important (47% overall) 4

---

Initiation Protocols by Formulation

Aripiprazole Monohydrate (Abilify Maintena)

Loading Strategy:

• Oral overlap: 14 days of oral aripiprazole required 5, 6
• Dosing window: ±7 days from scheduled injection 5
• Administration: IM (deltoid or gluteal) or SC
• Frequency: Monthly

If Missed Dose:

• Within ±7 days: Give next dose immediately
• Beyond 7 days: Restart 14-day oral bridge 5

---

Aripiprazole Lauroxil (Aristada)

Loading Strategy Options:

• One-day initiation: Single 675 mg injection + 30 mg oral aripiprazole × 21 days 7
• Standard: Oral aripiprazole × 21 days
• Aristada Initio: 675 mg loading dose + first maintenance dose same day (no oral needed) 7

Dosing intervals: Monthly, 6-week, or 2-month options Administration: IM (deltoid or gluteal)

If Missed Dose:

• Depends on interval and delay; may require oral supplementation or restart

---

Paliperidone Palmitate (Invega Sustenna/Trinza)

Loading Strategy:

• Day 1: 234 mg IM deltoid
• Day 8: 156 mg IM deltoid
• Maintenance: Monthly (Sustenna) or every 3 months (Trinza)
• No oral overlap required 6, 8

Dosing window: +14 days from scheduled injection 5

If Missed Dose:

• Within +14 days: Give next dose immediately
• Beyond 14 days: May require restart of loading regimen 5

---

Risperidone Microspheres (Risperdal Consta)

Loading Strategy:

• Oral overlap: 21 days of oral risperidone required 5, 6
• Frequency: Every 2 weeks
• Administration: IM (deltoid or gluteal)
• Reconstitution: Required (mixing needed)
• Refrigeration: Required

If Missed Dose:

• Beyond dosing window: Restart 21-day oral bridge 5

---

Risperidone In Situ Microparticles (Perseris)

Loading Strategy:

• Oral overlap: 21 days of oral risperidone 7
• Frequency: Monthly
• Administration: Subcutaneous (abdomen)
• No reconstitution needed

---

Olanzapine Pamoate (Zyprexa Relprevv)

Loading Strategy:

• Oral stabilization on olanzapine first
• Post-injection observation: 3 hours required (post-injection delirium/sedation syndrome risk) 8
• Frequency: Every 2 or 4 weeks
• Administration: IM (gluteal only)

Major Limitation: Mandatory 3-hour observation significantly limits use 8

---

Missed Dose Management Algorithm

Step 1: Determine Medication-Specific Window

• Aripiprazole monohydrate: ±7 days 5
• Paliperidone palmitate: +14 days 5
• Risperidone: Typically ±3-7 days for biweekly dosing
• Aripiprazole lauroxil: Varies by dosing interval

Step 2: Within Window

• Administer next dose as soon as possible
• Resume regular schedule from new injection date

Step 3: Beyond Window

• Aripiprazole products: Restart oral bridge (14-21 days) 5
• Risperidone products: Restart 21-day oral bridge 5
• Paliperidone: May require restart of loading regimen depending on delay 5

Step 4: Proactive Prevention

• Implement reminder systems (phone calls, texts) 5
• Involve family/caregivers in scheduling 5
• Schedule next appointment before patient leaves clinic

---

Switching Between LAIs

General Principles:

• Cross-titration based on half-life and receptor profile 3
• Consider pharmacokinetic overlap to prevent symptom breakthrough 7
• Account for delayed release characteristics of LAI formulations 8

Switching Strategy:

• From short-acting LAI to long-acting LAI: Ensure adequate overlap based on elimination half-life
• From oral to LAI: Follow initiation protocols above
• Between LAIs of same molecule: Direct conversion possible with dose adjustment
• Between different molecules: Gradual cross-titration preferred 3

---

Drug Interactions Requiring Dose Adjustment

CYP450 Inducers (Decrease LAI Levels):

• Carbamazepine: Reduces aripiprazole and risperidone levels significantly 5
• Action: Increase LAI dose or avoid combination; monitor for breakthrough symptoms

CYP450 Inhibitors (Increase LAI Levels):

• Fluvoxamine, fluoxetine: Increase antipsychotic concentrations 5
• Action: Reduce LAI dose by 25-50% 5

Tobacco Use:

• May affect pharmacokinetics; consider in dosing decisions 3

---

Adverse Effect Management

Drug-Induced Parkinsonism:

1. Reduce LAI dose (first-line) 5
2. Switch to lower-risk agent (aripiprazole-based products) 5
3. Anticholinergic medication (temporary, per APA guidelines) 1

Akathisia:

1. Reduce LAI dose 5
2. Short-term adjunctive treatment: Vitamin B6 or mirtazapine until dose adjustment reaches steady state 5
3. Switch to aripiprazole-based LAI (lower risk) 5
4. Beta-blockers or benzodiazepines (per APA guidelines) 1

Metabolic Effects:

• Olanzapine or clozapine: Offer concurrent metformin 3
• Monitor weight, glucose, lipids regularly

---

Common Pitfalls and How to Avoid Them

Pitfall 1: Inadequate Oral Overlap

• Risk: Symptom breakthrough during LAI loading phase
• Solution: Strictly adhere to oral supplementation periods (14-21 days for most agents) 5, 6

Pitfall 2: Missing Dosing Windows

• Risk: Subtherapeutic levels requiring restart of loading
• Solution: Proactive reminder systems and family involvement 5

Pitfall 3: Ignoring Drug Interactions

• Risk: Treatment failure or toxicity
• Solution: Screen for CYP450 inducers/inhibitors before LAI selection 5

Pitfall 4: Delayed Recognition of Side Effects

• Risk: Patient discontinuation and loss of adherence benefit
• Solution: Proactive monitoring and early dose adjustment rather than waiting for steady state 5

Pitfall 5: Using LAIs as "Last Resort"

• Risk: Missing opportunity for early intervention
• Solution: Normalize LAI discussion early in treatment, especially in first-episode psychosis 2

---

Practical Flow Chart Summary

Patient with Schizophrenia
         ↓
Poor adherence OR patient preference for LAI?
         ↓ YES
Assess side-effect priorities
         ↓
┌────────────────────────────────────┐
│ Metabolic concerns? → Aripiprazole │
│ EPS concerns? → Aripiprazole       │
│ Prolactin concerns? → Aripiprazole │
│ Cost/access priority? → Check      │
└────────────────────────────────────┘
         ↓
Select dosing interval preference
         ↓
┌──────────────────────────────────────┐
│ Monthly or longer preferred (63-82%) │
│ Avoid biweekly if possible           │
└──────────────────────────────────────┘
         ↓
Choose specific formulation
         ↓
Initiate with appropriate loading strategy
         ↓
┌─────────────────────────────────────────┐
│ Aripiprazole: 14-21 day oral overlap   │
│ Risperidone: 21 day oral overlap       │
│ Paliperidone: No oral overlap (loading)│
└─────────────────────────────────────────┘
         ↓
Implement reminder system
         ↓
Monitor for side effects and adjust dose early
         ↓
If missed dose: Check medication-specific window
         ↓
Within window? → Give next dose
Beyond window? → Restart oral bridge or loading

---

Maintenance Phase Considerations

Ongoing Monitoring:

• Effectiveness assessment: Every 4 weeks minimum 3
• Side effects: Proactive screening at each visit
• Metabolic parameters: Baseline and periodic (weight, glucose, lipids)
• Adherence to injection schedule: Track and intervene early

Duration of Treatment:

• Continue indefinitely if symptoms improved with antipsychotic 1
• Same medication preferred if effective 1
• Reassess if breakthrough symptoms after two adequate trials 3

Patient/Family Education:

• Normalize LAI use as proactive intervention, not punishment 2
• Discuss benefits: consistent delivery, reduced relapse, fewer hospitalizations 2
• Address misconceptions early in treatment 2
• Involve family in scheduling and monitoring 5